Amyloid Plaques

A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...

Drugmakers Eisai and Biogen are putting the Food and Drug Administration to the test with a request to approve a second Alzheimer’s drug that works like aducanumab (Aduhelm), the new, yet controversial,...

Participants who took donanemab for 76 weeks showed 32% slower decline in thinking and daily function compared with those in a placebo group.

Amyloid plaques accumulated faster in the brains of people who showed subtle difficulties in memory and learning tests.

People who are considered at risk for developing Alzheimer’s have abnormal brain function even before they develop amyloid plaques, a study published in the Journal of Neuroscience found.